Alexion Pharmaceuticals Inc. will pay $610 million in cash – and as much as $470 million in future milestone-based payments – to acquire Enobia Pharma Corp. Enobia is a biopharma company developing therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders. Enobia closed a $40 million round earlier this year, and was backed by investors including OrbiMed Advisors, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners.
You are browsing the archive for Desjardins Venture Capital - peHUB.
Technology company Coveo has appointed JP Provençal as senior vice president of business development. Reporting to Coveo chief executive officer Louis Tetu, Provençal will lead the company’s strategic alliances. Most recently Provençal was a resident entrepreneur at Montreal-based Desjardins Venture Capital, a $1 billion investment fund. Provençal served as consultant, coach and mentor to executives [...]
Enobia Pharma Inc., a Montreal-based biotech company developing therapeutics for bone disorders, has closed a $40 million round. The company’s backers include OrbiMed Advisors, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners. BofA Merrill Lynch acted as the exclusive placement agent to the company.
Research in Motion has acquired Tungle, maker of a Web-based meeting schedule tool. Tungle launched its technology in 2009, and has raised money from investors including Commonwealth Capital Ventures, JLA Ventures and Desjardins Venture Capital. Terms of the deal were not released. Tungle is based in Montreal.